December 19, 2023
The Administration Takes Aim At Drug Prices Again – This Time Through A Controversial Framework for Exercising March-In Rights
August 24, 2023
FDA Issues Draft Guidance for Obtaining Postmarket Data on Underrepresented Populations in Drug Clinical Trials
March 27, 2023
With Risk Comes Responsibility: EU Proposes High-Risk AI Regulation Affecting Device Manufacturers
March 7, 2023
FDA Issues Draft Guidance on “External Controls” in Clinical Trials to Support Safety and Efficacy of a Drug